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no alternative treatment option at that time, so 
the S ‑1 therapy was continued. Once the evalua‑
tion of the EGFR mutation in circulating tumor 
DNA in plasma samples became feasible, the pa‑
tient underwent the test and was found to have 
exon 19 deletion. As second ‑line therapy, she re‑
ceived 30 mg/d of afatinib, a second ‑generation 
EGFR ‑tyrosine kinase inhibitor (TKI). A follow‑
‑up chest computed tomography scan 1 month 
later showed reductions in the size of the prima‑
ry lesion and pulmonary metastases. The patient 
had continued to consult the ophthalmologist, 
but at 4 months after the initiation of afatinib 
therapy, the corneal findings improved marked‑
ly (Figure 1B). The best corrected visual acuity im‑
proved to 6/20 for the right eye and to 10/20 for 
the left eye. The patient is currently in good con‑
dition, and 4 months after the initiation of afa‑
tinib, she is able to work.
Corneal injury associated with cancer chemo‑
therapy is one of the complications that cannot 
be overlooked. Management by ophthalmologists 
is essential in this condition. Besides S ‑1,2 corneal 
complications have also been reported in patients 
receiving first ‑generation EGFR ‑TKIs, gefitinib3 or 
erlotinib,4 although these publications were only 
An 84 ‑year ‑old woman presented with a nodule 
in the left upper lobe of the lung, which was de‑
tected by mass screening. Examination of a trans‑
bronchial biopsy revealed the tumor to be lung 
adenocarcinoma; however, the epidermal growth 
factor receptor (EGFR) mutation could not be as‑
sessed because the specimen was too small. As 
the patient had a metastatic disease, she received 
outpatient chemotherapy using S ‑1, an oral fluo‑
ropyrimidine consisting of tegafur (a prodrug of 
fluorouracil), 5 ‑chloro ‑2,4 ‑dihydropyrimidine, 
and potassium oxonate.1 She received 7 cours‑
es of the chemotherapy (100 mg/d for 14 con‑
secutive days followed by a 2 ‑week rest period), 
and the response was evaluated as stable dis‑
ease. She was in a slowly progressive condition 
for 8 months since the initiation of chemother‑
apy and developed blurred vision. The best cor‑
rected visual acuity was 3/20 for the right eye 
and 6/20 for the left eye. A slit ‑lamp examination 
showed a hurricane ‑like irregularity of the cor‑
neal epithelium in both eyes (Figure 1A). Topi‑
cal antibiotic, topical steroid, and artificial tears 
were administered, but the symptoms did not im‑
prove during the S ‑1 therapy. However, consid‑
ering the patient’s general condition, there was 
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Kraków 2018 Figure 1 Slit ‑lamp examination of the eyes: A – a hurricane ‑like irregularity of corneal epithelium in both eyes
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case reports or case series. Afatinib, a second‑
‑generation EGFR ‑TKI, is widely used in patients 
with advanced non–small cell lung cancer and its 
clinical utility is now highly evaluated.5 It is inter‑
esting that corneal complications due to S ‑1 im‑
proved after switching the drug to afatinib. How‑
ever, the mechanism why the S ‑1–induced corne‑
al complication improved remains unknown. This 
observation suggests that afatinib may be a ther‑
apeutic option for patients with the EGFR mu‑
tation who develop corneal complications during 
the use of S ‑1 therapy or first ‑generation EGFR‑
‑TKIs. We report a rare case with improvement 
of S ‑1–induced corneal complication by treat‑
ment change to afatinib. Corneal complication 
should be considered in patients complaining of 
blurred vision during anticancer treatment with 
some anticancer drugs such as S ‑1 or EGFR ‑TKIs.
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Figure 1 Slit‑lamp 
examination of the eyes  
B – a marked improvement 
of corneal findings 
at 4 months after 
the initiation of afatinib 
therapy
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